Publications

and Scientific Papers

Process development of tangential flow filtration and sterile filtration for manufacturing of mRNA-lipid nanoparticles: A study on membrane performance and filtration modeling

Process development of tangential flow filtration and sterile filtration for manufacturing of mRNA-lipid nanoparticles: A study on membrane performance and filtration modeling

Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice

Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice

A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection

A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection

Therapeutic mRNA cancer vaccine for GBM reaches complete response in a pre-clinical model

Therapeutic mRNA cancer vaccine for GBM reaches complete response in a pre-clinical model

Comparison of modified T7 RNAPs to develop a simplified, cost effective, robust mRNA production process

Comparison of modified T7 RNAPs to develop a simplified, cost effective, robust mRNA production process

Novel LNP delivered mRNA vaccine elicits potent immune responses and cures established tumor in mice

Novel LNP delivered mRNA vaccine elicits potent immune responses and cures established tumor in mice

Next-Generation LNP's Induce Effective Anti-Tumor T cell Responses

Next-Generation LNP's Induce Effective Anti-Tumor T cell Responses

Next-Generation mRNA-LNP Vaccine Prototype Achieves Tumor Clearance in a GBM Mouse Model

Next-Generation mRNA-LNP Vaccine Prototype Achieves Tumor Clearance in a GBM Mouse Model

Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study

Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study

Phase I randomized, observer‑blinded, placebo‑controlled study of a SARS‑CoV‑2 mRNA vaccine PTX‑COVID19‑B

Phase I randomized, observer‑blinded, placebo‑controlled study of a SARS‑CoV‑2 mRNA vaccine PTX‑COVID19‑B

In vivo Characterization of T-Cell Activating Disulfide Lipids

In vivo Characterization of T-Cell Activating Disulfide Lipids

Preclinical Evaluation of a SARS-CoV-2 mRNA Vaccine PTX-COVID19-B

Preclinical Evaluation of a SARS-CoV-2 mRNA Vaccine PTX-COVID19-B